Jodie Morrison, Q32 Bio CEO
November 16, 2023 08:44 AM ESTUpdated 03:01 PM
Startups
Deals

Q32 Bio to take Ho­mol­o­gy Med­i­cines’ Nas­daq spot to fund PhII tri­als in au­toim­mune, in­flam­ma­to­ry con­di­tions

Kyle LaHucik

Senior Reporter

The re­verse merg­ers are flow­ing. Q32 Bio will take Ho­mol­o­gy Med­i­cines’ place on the Nas­daq, the com­pa­nies said Thurs­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

A service from the Financial Times